Nonparametric and Semiparametric Group Sequential Methods for Comparing Accuracy of Diagnostic Tests by Tang, Liansheng et al.
UW Biostatistics Working Paper Series
10-22-2007
Nonparametric and Semiparametric Group
Sequential Methods for Comparing Accuracy of
Diagnostic Tests
Liansheng Tang
George Mason University, ltang1@gmu.edu
Scott S. Emerson
University of Washington, semerson@u.washington.edu
Xiao-Hua Zhou
University of Washington, azhou@u.washington.edu
This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the
copyright holder.
Copyright © 2011 by the authors
Suggested Citation
Tang, Liansheng; Emerson, Scott S.; and Zhou, Xiao-Hua, "Nonparametric and Semiparametric Group Sequential Methods for
Comparing Accuracy of Diagnostic Tests" (October 2007). UW Biostatistics Working Paper Series. Working Paper 316.
http://biostats.bepress.com/uwbiostat/paper316
Nonparametric and Semiparametric Group Sequential Methodsfor Comparing Accuracy of Diagnostic Tests 1
1. Introduction
Medical tests for diagnosis of disease are often based on the comparison of some biologic
measurement to some threshold. In evaluating the utility of a particular test and thresh-
old, it is common to consider its sensitivity (the probability that a truly diseased patient
has a “positive” test exceeding the threshold) and the speciﬁcity (the probability that a
truly healthy patient has a “negative” test in which the measurement does not exceed the
threshold). However, the optimal threshold for any such biologic measurement depends on
the prevalence of disease in the screened population and costs associated with incorrect
diagnoses. It is thus common to compare two diagnostic tests with respect to their receiver
operating characteristic (ROC) curves: plots of the relationship between the true positive rate
(the sensitivity) and the false positive rate (FPR) (one minus the speciﬁcity) as the choice of
threshold varies. When the ROC curve for one diagnostic test is uniformly greater than the
ROC curve for another diagnostic test, the use of the ﬁrst test will tend to engender lower
costs from misdiagnosis no matter the magnitude of costs assigned to each type of diagnostic
error and no matter the prevalence of disease in the screened population. As a measure of the
tendency for the ROC curve for one test to dominate another in this manner, it is common
for investigators to consider the area under each ROC curve (AUC) Diagnostic tests with the
larger AUC are deemed superior. However, when the ROC curve of a test does not dominate
that of another test, the AUC may not be a good measure to use for the comparison of two
tests. Other measures, such as the partial area under the ROC curve within some range of
acceptable speciﬁcity or sensitivity (pAUC), or some weighted average of the ROC curve
(wAUC), should be used instead (see Zhou et al., 2002 for a more complete discussion).
Scientiﬁc studies designed to compare the utility of two diagnostic tests will typically
use samples of diseased and healthy subjects as deﬁned by some gold standard. Statistical
analysis of the resulting data will focus on whether any diﬀerence in AUC (pAUC, or wAUC)
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is statistically signiﬁcant. Statistical methods for comparing ROC curves might be parametric
(e.g., the binormal model of Dorfman and Alf, 1969), semiparametric (Cai and Pepe, 2002),
or nonparametric (Hanley and McNeil, 1982; Wieand et al., 1989). Molodianovitch, et al.
(2005) provided a comprehensive study on nonparametric approaches for comparing AUCs.
In scientiﬁc studies that evaluate diagnostic tests, human experimentation raises issues
related to ethics and eﬃciency. Interim analyses conducted at one or more times during the
accrual of data in such studies can greatly improve the ability to address those ethical and
eﬃciency issues. Such group sequential monitoring of clinical trials is commonplace, but the
use of sequential sampling when evaluating diagnostic tests has not received much attention
to date. Mazumdar & Liu (2003) provided a parametric sequential method for testing the
equality of two AUCs when the observations in the healthy and diseased populations follow
normal distributions (the “binormal model”). Zhou et al. (2007) proposed a nonparametric
method for sequentially comparing AUCs. Mazumdar (2004) provided a general guideline
for performing sequential tests for diagnostic accuracy studies based on AUCs.
Sequential tests are particularly valuable for comparative diagnostic trials in medical
imaging modalities. Commonly used imaging procedures include Computed Tomography
(CT) and Positron Emission Tomography (PET). However, CT scanners expose the subjects
to ionizing radiation from a series of X-rays. In PET, subjects have to undergo the injection
of radioactive isotopes in order for their regions of interest to be measured. Unnecessarily
exposing the subjects in the scientiﬁc study to an inferior diagnostic procedure is clearly
undesirable. Furthermore, unnecessarily delaying the identiﬁcation of a beneﬁcial diagnostic
test does a disservice to those patients who are not participating in the scientiﬁc study, but
would beneﬁt from more accurate diagnosis. As both PET and CT are expensive procedures
costing as high as thousands of dollars per subject, unnecessarily prolonging a study also
diverts resources from better uses.
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Wieand, Gail, James and & James (1989) introduced wAUC estimators and the subse-
quent WGJJ statistic for comparing two ROC curves is the diﬀerence between two wAUC
estimators. The contribution made by this article is that we show a sequentially computed
modiﬁcation of this WGJJ statistic has approximately uncorrelated increments covariance
structure by deriving its asymptotic properties using a basic theorem in empirical process
theory, therefore, allowing the use of all popular group sequential methods introduced in
Jennison & Turnbull (2000). One advantage of wAUC estimators over parametric AUC
estimators in Mazumdar & Liu (2003) is that the wAUC estimator is distribution-free and
includes a large family of statistics in diagnostic tests, such as non-parametric estimators of
AUC, partial AUC, and the sensitivity at a speciﬁed speciﬁcity. The wAUC estimator also
includes the AUC estimator in Zhou et al. (2007) as a special case.
The paper is organized as follows. In Section 2 we show that after a speciﬁc transformation
the WGJJ statistic is a Brownian motion process as information time grows, therefore, it can
be applied in sequential tests. In Section 3 we describe the design and monitoring procedure
for comparing the wAUC’s in group sequential designs. In Section 4 we describe the use in
ROC curve analysis of a sequential semiparametric estimator based on proportional hazard
models. In Section 5 we carry out simulations to investigate the eﬃciency of these estimators
under various settings. The nonparametric method is illustrated in Section 6 in the setting
of lung cancer diagnosis and some discussion is presented in Section 7.
2. Asymptotic distribution of sequential WGJJ statistic
Suppose we have measurements from two diagnostic tests on m diseased subjects and n
healthy subjects, where all subjects are totally independent. Denote the measurements from
test  ( = 1, 2) on the ith diseased subject as Xi and the corresponding measurements
on the jth healthy subject as Yj. Deﬁne joint cumulative survivor distribution functions
(X1i, X2i) ∼ F¯ (x1, x2) for the diseased population’s measurements and (Y1j, Y2j) ∼ G¯(y1, y2)
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for the healthy population’s measurements. Further deﬁne marginal survivor distributions
Xi ∼ F¯(x) and Yj ∼ G¯(y).
Without loss of generality, we assume that measurements tend to be larger for diseased
subjects than for healthy subjects. A receiver operating characteristic (ROC) curve for the th
test can be expressed as a plot of sensitivity (Pr(Xi > c) = F¯(c)) versus false positive rate
(FPR), or 1 minus the speciﬁcity (Pr(Yj > c) = G¯(c)) as the threshold c varies over the real
numbers. Equivalently, we can deﬁne the ROC curve for test  as ROC(u) = F¯
(
G¯−1 (u)
)
,
where 0  u  1, noting that in this parameterization u corresponds to the FPR.
Wieand et al. (1989) proposed comparing two ROC curves on the basis of the weighted
area under the ROC curve Ω =
∫ 1
0
[F¯(G¯
−1
 (u))]dW (u), with a probability measure W (u)
deﬁned on the FPR, u, for u ∈ (0, 1). Included in this class of accuracy measures are the
area under the curve (AUC) (when W (u) = u for 0 < u < 1), the partial area under the
curve (pAUC) between FPRs u1 and u2 (when W (u) = u for 0 < u1  u  u2  1), and the
sensitivity at a given level of speciﬁcity u0 (when W (u) is a point mass at u0).
In particular, Wieand et al. (1989) considered a nonparametric estimator based on empiri-
cal survivor distribution functions ˆ¯F(x) and
ˆ¯G(y). Two diagnostic tests are then compared
using the diﬀerence Δ in two wAUC estimators as estimated by
Δˆ = Ωˆ1 − Ωˆ2 =
∫ 1
0
{
ˆ¯F1(
ˆ¯G−11 (u))
}
dW (u)−
∫ 1
0
{
ˆ¯F2(
ˆ¯G−12 (u))
}
dW (u). (1)
In Wieand et al. (1989)’s paper, they derived the asymptotic property of Δˆ. However, their
proof was complicated. The use of modern empirical theory can greatly simplify the proof.
Here we re-derive the asymptotic distribution of Δˆ in Theorem 1 by applying Lemma 3.9.27
of Van der Vaart & Wellner (1996) to the derivative of the functional composition, because
the estimator Ωˆ can be written as the sum of two independent Brownian bridges. The proof
of Theorem 1 is provided in the Appendix.
THEOREM 1. Under mild regularity conditions, when m/n → λ < ∞ as m,n → ∞, the
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diﬀerence Δˆ = Ωˆ1 − Ωˆ2 satisﬁes
√
m(Δˆ−Δ) D−→ N (0, vX + λvY ),
where vX and vY are given in the Appendix.
The approximate variance σ2Δ of Δˆ is then σ
2
Δ = vX/m + vY /n and can be estimated by
substituting the corresponding empirical estimates in vX and vY in Equation (A.1) in the
Appendix. Using the above distributional theory, we can make statistical inference about
Δ by using the nonparametric estimator Δˆ with its approximately (large sample) normal
distribution, N (Δ, σ2Δ). In particular, hypothesis tests of H0 : Δ = Δ0 can be based on the
normalized statistic Z = (Δˆ−Δ0)/σˆΔ. In the presence of large sample sizes and the absence
of early stopping, the Z statistic has the approximately standard normal distribution under
H0. The use of this statistic in the group sequential setting is described in the next section.
3. Use of the WGJJ statistic under group sequential sampling
3.1 Stopping Rules
We consider now a group sequential sampling plan involving up to J analyses of the accruing
data. At the time of the jth analysis, we have diagnostic test data available on the ﬁrst mj
diseased subjects and the ﬁrst nj healthy subjects. From these data available at the jth
analysis, we compute for the th diagnostic test the empirical survivor distribution functions
ˆ¯Fj(x) and
ˆ¯Gj and wAUC estimators Ωˆj. These interim estimates are then used to compare
ROC curves using interim contrast Δˆj, its standard error σΔj, and the interim normalized
statistic Zj = Δˆj/σΔj.
We consider a group sequential sampling plan deﬁned by up to four boundaries −∞ 
aj  bj  cj  dj ∞ at each of the J analyses. In order to uniquely deﬁne a stopping rule,
we demand for j < J that either aj < bj or cj < dj (or both) and that at least one of the
four boundaries are ﬁnite. It is also typical that we obtain termination with a ﬁnite sample
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size by ensuring that aJ = bJ and cJ = dJ for some ﬁnite (but possibly random) choices of
J , mJ , and nJ .
Sequential sampling proceeds by starting at analysis j = 1. At the jth analysis, mea-
surements on the ﬁrst mj diseased subjects and nj healthy subjects are used to compute
the interim statistic Zj. If Zj  aj, bj < Zj < cj, or Zj  dj, the study is stopped without
accruing more subjects. Otherwise, the study accrues suﬃcient subjects to be able to proceed
to analysis j +1. We deﬁne group sequential statistic (M˜, Z) by M˜ = min{1  j  J : Zj ∈
(aj, bj]∪ [cj, dj)} and Z = ZM˜ . In the setting of comparing ROC curves, we would most often
decide that diagnostic test 1 is superior, approximately equivalent, or inferior to diagnostic
test 2 according to whether Z  dM˜ , bM˜ < Z < cM˜ , or Z  aM˜ , respectively.
When frequentist statistical inference is the ultimate goal, it is common to ensure that
the experimentwise error is controlled at a desired level (e.g., in a two sided hypothesis test
choose stopping boundaries to ensure Pr(bM˜ < Z < cM˜ |H0) = 1 − α for a desired type
I error α). The dimensionality of the boundary space is typically reduced through the use
of a boundary shape function which deﬁnes a relationship between the exact value of the
stopping boundaries aj, bj, cj, dj and the statistical information available at the jth analysis
(which is typically 1/σ2Δj in the case of an approximately normally distributed statistic). For
purposes of sample size calculation, the boundary shape function typically speciﬁed in terms
of the proportion τj of maximal statistical information available at each analysis (in the case
of approximately normally distributed statistics τj = σ
2
Δj/σ
2
Δj). Commonly cited boundary
shape functions include the O’Brien-Fleming, the triangular test boundary, and the Pocock
boundaries (see Jennison & Turnbull, 2000).
The statistical literature is replete with alternative strategies for choosing stopping bound-
aries appropriate for particular scientiﬁc and statistical settings (see Jennison & Turnbull,
2000; Emerson, Kittelson, & Gillen, 2007a, b). Almost all of that statistical literature,
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and all three of the commercially available statistical software capable of implementing the
general methods (S+SeqTrial, PEST, EaSt), presume a particular covariance structure for
the statistics Z1, Z2, . . . , ZJ . In this covariance structure, the statistical information accrued
between two successive analyses is independent of all prior information accrued, and it is
thus commonly referred to as an “independent increment” covariance structure (Jennison &
Turnbull, 2000, Chapter 11).
The use of the WGJJ statistic in the sequential comparison of ROC curves is greatly
facilitated by showing that the statistic has an “independent increment” structure. We let Ij
denote the statistical information at the jth analysis, and τj = Ij/IJ denote the proportion
of maximal information as before. Deﬁne B(τj) =
√
τjIjΔˆj, which is an asymptotically
unbiased estimator for
√
τjIjΔ = τj
√
IJΔ = with asymptotic variance var(B(τj)) = τj.
THEOREM 2. For j < k, cov(B(τj), B(τk)) = τj.
The proof is provided in the Appendix. Thus B(τj) behaves asymptotically like a Brownian
motion process with a drift parameter θ, where θ = Δ
√
IJ . The WGJJ estimator can then
be readily accommodated by standard group sequential software.
3.2 Sample size determination
In a wide variety of statistical models, the maximal number N˜J of sampling units needed is
estimated by N˜J = δ
2
αβV/Δ
2
1, where 1/V is the (average) statistical information contributed
by a single sampling unit, Δ1 is the diﬀerence between Ω’s under the alternative hypothesis
to be detected with statistical power 1−β in a level α hypothesis test, and δαβ is the design
alternative in some standardized version of the test. For instance, in a ﬁxed sample (no
interim analyses, J = 1) two-sided hypothesis test of the diﬀerence in weighted AUCs having
equal sample sizes, N˜J might be the sample size to be accrued in each group, Δ1 = Ω1 −Ω2
might be the diﬀerence between group means under the design alternative, V = σ2Δ is the
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variance, and δαβ = z1−α/2 + zβ. This same formula can be used in a group sequential test,
providing that the value of δαβ speciﬁc to the selected stopping rule is used.
With pilot data, it is trivial to nonparametrically calculate the variance of the WGJJ statis-
tic from Equation (2). However, if the pilot study is not yet available, we will nevertheless
need parametric distribution assumptions to obtain the variance of the WGJJ statistic based
on the formula in Equation (2). This means that we will have to guess explicit distributional
models and parameters in the models. In the following context, we will discuss a method
to obtain conservative sample sizes based on the conjectured values of AUCs without either
having a pilot data or specifying model parameters.
We denote the WGJJ statistic for AUCs as ΔA. ΔA is then the diﬀerence between two
Wilcoxon statistics, ΩˆA1 and Ωˆ
A
2 . Hanley & McNeil (1982) showed that an estimated AUC had
a smaller variance under negative exponential models than under normal or gamma distri-
butions, therefore, a more conservative sample size under negative exponential distribution.
More importantly, the advantage of using negative exponential distributions rather than nor-
mal or gamma distributions is that we can derive the variance of ΩˆA solely from hypothesized
values of AUCs , ΩA , without prespeciﬁed parameters. Sample sizes for two diagnostic arms
can then be calculated without knowing the parameters in negative exponential distributions
as stated in the following theorem.
THEOREM 3. Under mild regularity conditions, as m/n → λ when m,n → ∞, the
variance v2A of Δ
A is then given by v2A = var(Ωˆ
A
1 ) + var(Ωˆ
A
2 )− 2ρ
√
var(ΩˆA1 )var(Ωˆ
A
2 ), where
var(
√
mΩˆA ) = λQ1 +Q2− (λ+1)(ΩA )2, with Q1 = ΩA /(2−ΩA ), Q2 = 2(ΩA )2/(1 +ΩA )
and ρ, the correlation between two AUCs.
Proof. With ﬁnite sample sizes m and n, we have
var(ΩˆA ) =
[
ΩA (1− ΩA ) + (m− 1){Q1 − (ΩA )2}+ (n− 1){Q2 − (ΩA )2}
]
/mn.
Thus, as m,n →∞, it is true that var(√mΩˆA )→ λQ1 + Q2 − (λ + 1)(ΩA )2.
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Denote V˜ to be the right side of the above equation. Consider a null hypothese, H0 : Δ
A = 0
and the alternative two-sided hypothesis, HA : Δ
A = 0 with Type I error α and power 1− β
at the conjectured AUC values, ΩA1 and Ω
A
2 . Using a general formula in Zhou et al. (2002,
Section 6.2), the required ﬁxed sample sizes for the diseased and healthy subjects, denoted
as Mf and Nf respectively, can be derived by
Mf = λNf =
(Z1−α/2
√
(2− 2ρ)V˜1 + Z1−β
√
V˜1 + V˜2 − 2ρ
√
V˜1V˜2)
2
(ΩA1 − ΩA2 )2
. (2)
A special case with λ = 1 and ρ = 0 is given in Hanley and McNeil (1982). Subsequently,
the maximum sample sizes Mg for the diseased subjects and Ng for the healthy subjects
can be derived for the O’Brien-Fleming test, the triangular test, and the Pocock test by
Mg = λNg = δ
2
αβ,g/δ
2
αβ,fMf , where δ
2
αβ,g/δ
2
αβ,f is the sample size ratio between a ﬁxed sample
design and a sequential design. We can also get the maximum sample sizes Me and Ne for a
more ﬂexible error spending function design (Lan & DeMets, 1983) by Me = λNe = θ
2
e/θ
2
fMf ,
where θf and θe are the drift values for a ﬁxed sample design and a group sequential design,
respectively.
Not restricted to the two-sided hypothesis test mentioned above, the sample size can be
determined for any stopping rule in Section 3.1. These test methods were incorporated in
S+SeqTrial (2000) developed by Emerson and others. Their software provides a compre-
hensive tool for designing, monitoring, and analyzing clinical trials using group sequential
methods. The independent increment covariance structure of the WGJJ statistic ensures
its ready accommodation by the software. In S+SeqTrial, we can specify the type of group
sequential design in S+SeqTrial, then plug in the conjectured value for a wAUC, with its
variance, the desired power and type I error to obtain the total size without calculating both
ﬁxed sample size and the ratio λ.
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4. Semiparametric partial AUC estimator
When the measurements of diagnostic tests are from exponential distributions or other
power-law distributions, the proportional hazard model assumption is satisﬁed (for a real
example, see Sanchez-Marin and Padilla-Medina, 2006). We can then use a semiparametric
estimator for comparing correlated AUCs under proportional hazard models. Let Zi = 1 if
the ith subject is diseased, 0 otherwise, under the th diagnostic test with  = 1, 2. Now
the th test of the ith subject has a hazard function λi(t) = λ0(t)exp{γZi}, where λ0(t)
is a baseline hazard function and γ’s are parameters in the Cox regression. The resulting
ROC curve for the th test takes on the form of ROC(u) = u
exp(γ). Its AUC is given by
ΩA(γ) = 1/{exp(γ) + 1}, and its partial AUC between a and b, 0 < a < b  1, is given
by ΩpA(γˆ) = {bexp(γˆ)+1 − aexp(γˆ)+1}/{exp(γˆ) + 1}. If 0 = a < b  1, the partial AUC is
ΩpA(γˆ) = b
exp(γˆ)+1/{exp(γˆ) + 1}. The covariate-adjusted estimator γˆ is obtained from the
marginal Cox regression model for the th test. The asymptotical property of γˆ’s is shown
in Wei et al. (1989) by
n1/2(γˆ1 − γ1, γˆ2 − γ2) D−→ N(0, v1Σγv2),
where v = var(γˆ) and Σ
γ is the correlation matrix of n1/2(γˆ1 − γ1, γˆ2 − γ2).
THEOREM 4. As m,n → ∞, the estimated AUC (or partial AUC) diﬀerence, Δ(γˆ1, γˆ2),
satisﬁes
n1/2(Δ(γˆ1, γˆ2)−Δ(γ1, γ2)) D−→ N(0, v2p),
where
v2p =
⎛
⎜⎝ (Ω)
′(γ1)
−(Ω)′(γ2)
⎞
⎟⎠
′
Σγ
⎛
⎜⎝ (Ω)
′(γ1)
−(Ω)′(γ2)
⎞
⎟⎠ .
Its proof in a general survival model framework is provided in the Appendix. Consequently,
the sequential versions of our semiparametric proportional hazard AUC or pAUC estimators
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have asymptotically independent increments. Thus, it is straightforward to incorporate the
semiparametric estimators in the group sequential designs. Our estimator is also easily
adapted for sequentially testing survival outcome measurements from two diagnostic tests.
The covariance matrix Σγ between γ’s can be consistently estimated using a sandwich
estimator (Wei et al., 1989) by Σˆγ = nvˆ1W1W
′
2vˆ2, where vˆ is the estimated variances for γˆ,
and W is the residual vector calculated from the marginal proportional hazard model for
the th test.
5. Finite-sample property
In this simulation study, we investigated the ﬁnite sample performance of the sequential
WGJJ statistic and the previously described semiparametric procedure both in a ﬁxed sample
test (J = 1), a three-group sequential test (J = 3), a four-group sequential test (J = 4) and a
ﬁve-group sequential test (J = 5). We also included a common binormal parametric approach
for comparisons among these three methods. The null hypothesis of equal AUCs was set to
be true and the nominal type I error was set to be 0.05 for two-sided tests. We simulated
bivariate normal (Binorm) , bivariate lognormal (Bilog) and bivariate exponential (Biexp)
data as outcome measurements for two diagnostic tests. The bivariate normal models had
the forms of (X1, X2) ∼ N((11, 1),Σ1) and (Y1, Y2) ∼ N((10, 0),Σ2), where
Σ1 =
⎛
⎜⎝ 1
√
2ρ
√
2ρ 2
⎞
⎟⎠ and Σ2 =
⎛
⎜⎝ 2
√
2ρ
√
2ρ 1
⎞
⎟⎠ , with ρ = 0.5.
The AUCs were thus the same from the formula of AUC under binormal models (Zhou
et al., 2002): AUC = Φ{(μ1 − μ0)/(
√
σ21 + σ
2
0)}, where (μ1, σ1) and (μ0, σ0) are the
normal parameters in diseased and healthy groups, respectively. The bivariate lognormal
models had the forms of exp(X1, X2) and exp(Y1, Y2) for the diseased and healthy subjects,
respectively. The AUCs under simulated lognormal models were also equal, since ROC curves
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are invariant to monotone transformations. Equal numbers of diseased and healthy subjects
were considered in the simulation, i.e., m=n=(50, 100, 200).
The bivariate exponential random variables were simulated using an algorithm in Gumbel
(1960). The Gumbel’s distribution had the form H(x, y) = H1(x)H2(y)[1+4ρ{1−H1(x)}{1−
H2(y)}], where ρ ∈ [−0.25, 0.25]. We set ρ to be 0.25. Bivariate exponential random variables
were simulated with the marginal survival functions exp(−β1x) and exp(−β2y) for diseased
and healthy subjects respectively, where  = 1, 2, denotes the types of tests. In the simulation,
(β11, β12, β21, β22) = (1, 2, 2, 4). Since the AUCs under these exponential distributions are
given by exp(γ) = β1/β2, two resulting AUCs should be the same.
Under each of the above model assumptions, 1000 random variables were simulated and
three methods including sequential WGJJ statistic, semiparametric method and parametric
binormal method were ﬁtted to the simulated data. The Z statistics were then calculated
based on estimated parameters and their variances. The rejection rates were obtained by
comparing the Z statistics with corresponding test boundaries under either the ﬁxed sample
design or sequential designs. Table 1 gives the rejection rates of all three methods with a
nominal level 0.05 under both Pocock’s (POC) and O’Brien & Fleming’s (OBF) criterions.
In the ﬁxed sample test, the WGJJ statistic gives the rejection rate close to the nominal
level under all model speciﬁcations for sample sizes in both groups as small as 50, while the
parametric binormal method greatly inﬂates rejection rates when the true underlying distri-
bution is bivariate lognormal, and deﬂates rejection rates when the underlying distribution
is in fact bivariate exponential. Under the setting of group sequential designs, the WGJJ
statistic also give correct rejection rates regardless of underlying distribution models. When
the underlying distributions are misspeciﬁed, the parametric and semiparametric methods
inﬂate the rejection rates further compared with their ﬁxed-sample counterparts. In addition,
with proportional hazard model correctly speciﬁed, the semiparametric method performs well
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for both the ﬁxed sample design and the sequential designs. In summary, the nonparametric
approach based on the WGJJ statistic is robust to model speciﬁcations and it performs as
well as parametric approach under correct model assumptions. Moreover, the nonparametric
approach has excellent small-sample performance, which makes it a well-suited method for
conducting group sequential diagnostic trials.
[Table 1 about here.]
6. Examples
6.1 An illustration for sample size determination
We used binormal and biexponential models to illustrate how to determine maximum sample
sizes in the ﬁxed sample design and group sequential design using the WGJJ statistic for
AUC and partial AUC estimators, which are denoted as ΔA and ΔpA, respectively. The
equally-spaced symmetric two-sided error spending (Kim & Demets, 1992) test with the error
spending function f(τ) = min(ατ, α) was used with power 0.8 and type I error α = .05.
6.1.1 Under bivariate normal model assumption. Suppose the binormal distribution of
the test outcomes is given by (X1, X2) ∼ N((μ1, μ2),Σ), (Y1, Y2) ∼ N((0, 0),Σ), where
covariance matrix Σ had common variances 1 and covariances 0.5. We let λ = 1, equivalent
to disease prevalence 0.5. Since the distributions were known, we were able to obtain the
exact variance of ΔA or ΔpA from the results in Equation (A.1) in the Appendix. Under the
speciﬁed test setting, we obtained sample sizes Ng from the results in Section 3.2. Here, the
drift value θe = 2.96 for a sequential design and θf = 2.80 for a ﬁxed sample design can be
calculated using aforementioned softwares. The sample sizes Nf for the ﬁxed sample design
can then be computed. The results for ΔA are presented in Table 2. We also found that the
sample sizes given by Equation (2) under the same test setting are slightly more than those
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in Table 2. This ensures that without the pilot data or prior knowledge of the distributions,
the sample size computed by Equation (2) can serve as a conservative initial guess.
To investigate how accurate these sample sizes are in maintaining the required power, we
used several relatively large sample sizes in Table 2, such as size 929 (AUC 0.75 vs AUC
0.70), size 634 (AUC 0.85 vs 0.80) and size 91 (AUC 0.85 vs AUC 0.70) in a three group
design. We simulated 1000 data sets under each binormal setting, and computed the number
of times that the null hypothesis of equal AUCs was rejected. The resulting powers under
aforementioned sample sizes were then 80.3%, 79.5% and 78.7%, respectively. They were
close to the nominal level 80%.
[Table 2 about here.]
Suppose now we are interested in comparing partial AUCs for the false positive rate less
than 0.6. For our range of false positive rate, it can be calculated that the partial AUC is
between 0.18 and 0.6 (Zhou et al., 2002, Section 4). Table 2 also gives maximum possible
sample sizes for testing the diﬀerence between partial AUCs.
These two sets of illustrations gave examples of deriving the maximum sample sizes for
three-group sequential designs if the distributions of test outcomes are assumed known. In
fact, given a speciﬁed power and a type I error, available softwares such as S+SeqTrial,
PEST and EaSt can compute sample size ratios for Pocock, OBF, and error spending tests.
If the required sample size for the ﬁxed sample test is available, the maximum sample size for
any sequential test can be derived by multiplying a speciﬁed constant ratio related to that
sequential test. In the case that the models are unknown, if the pilot data is available, then
the consistent estimates of vX and vY are obtained by plugging in the empirical distributions
and quantiles and substituting the empirical estimates of r1(u) and r2(u) in Equation (A.1)
in the Appendix, respectively.
At the ﬁrst glance of Table 2, one may notice that the maximum sample sizes of the group
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sequential test are larger than those of the ﬁxed sample test. This is because these maximum
sample sizes only occur in the worst scenario when group sequential tests are carried all
the way to the end. Often sequential tests terminate earlier before the maximum number of
subjects are recruited. Therefore, looking at expected sample sizes reveals the advantage of
sequential trials. We calculated the expected sample sizes with the speciﬁed error spending
test for the three group test. The fact that the expected sizes are about 81% of those of the
ﬁxed sample test ensures the early stopping of the group sequential design.
6.1.2 Under bivariate exponential model assumption. A bivariate exponential distribution
in Gumbel (1960) was used to calculate the variance of the WGJJ estimator and that
of the newly proposed semiparametric estimator. The Gumbel’s distribution has the form
H(x, y, ρ) = H1(x)H2(y)[1 + 4ρ(1−H1(x))(1−H2(y))], where ρ ∈ [−0.25, 0.25]. Here ρ was
set to be 0.25 in this simulation study. For diseased and healthy groups, bivariate exponential
random variables had marginal survival function of exp(−β1x) and exp(−β2y) for test 1
and 2. We let β12 = β22 = 1. The values of β11 and β21 corresponded to the AUCs (or pAUCs)
in Table 3. We let λ = 1 in the sample size calculation with the speciﬁed test setting. Not
surprisingly, the nonparametric and semiparametric methods give the same sample sizes
when comparing AUCs or pAUCs. The maximum possible sample sizes are listed in Table 3
for AUCs and partial AUCs.
[Table 3 about here.]
6.2 Sequential lung cancer diagnostic trial
Lung cancer is one of the most common cancers in the world and is the leading cause of
cancer death in the United States. The lung cancer is categorized into two types: small cell
and non-small cell. The non-small cell lung cancer is the most common type which is only
curable with surgery in its early stages. Computed Tomography (CT) and Positron Emission
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Tomography (PET) are both the pre-operative scanning tests for the staging of non-small cell
lung cancer. CT, a traditional diagnostic tool, does not perform well to diﬀerentiate between
benign and malignant lesions. PET, a new scanning technique, provides higher resolution
image with detailed view of regions of interest. But the results of PET are usually aﬀected
by muscle and inﬂammatory activities, which are considered to be factors of imprecision
locations of abnormalities. Comparing the diagnostic performance of these two techniques is
of extensive interest of radiologists (Lardinois et al., 2003; Silvestri et al., 2003). The gold
standard in these tests is pathology results from biopsy specimens.
The staging accuracy of non-small cell lung cancer is usually between 52% and 85% for
CT and between 81% and 96% for PET (Lardinois et al., 2003; and Silvestri et al., 2003).
Consider testing the null hypothesis of equal AUCs against the two-sided alternative with
power 0.8 and signiﬁcance level 0.05. A possible initial alternative is likely to be 15% which
is diﬀerence between 70% for CT and 85% for PET. If an investigator is interested in a
nonparametric AUC estimator, corresponding to two-sample Wilcoxon statistics (Hanley &
McNeil, 1983), as an accuracy measure in a ﬁxed sample lung cancer trial to compare CT
and PET, the maximum sample size is 81 under power 0.8, type I error 0.05 under the
binormal assumption according to Table 2. If the outcome measurements are assumed to
be from bivariate exponentials, totally 109 subjects in both arms would be required from
Table 3. However, as mentioned in the Introduction, these diagnostic methods are expensive
and carries some safety risks. While carrying out clinical trials to compare CT and PET,
the results need to be monitored repeatedly to ensure that human subjects are not exposed
to inferior scanning techniques. In negative trials that show equivalence of the accuracy
of CT and PET, the trials need to be terminated early and the subjects can be switched
to compare CT with other scanning techniques which involves combining CT and PET,
or recently developed Magnetic Resonance Imaging technique. If PET is found to be more
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accurate than CT in the early interim analysis, it means that PET scan in staging the
non-small cell lung cancer could be preferred over CT scan and should be performed more
frequently in lung cancer diagnosis.
Suppose we want to design a three-group error spending test with the error spending
function f(τ) = min(ατ, α). The equally-spaced symmetric two-sided test with signiﬁcance
level 0.05 and power 0.8 would need maximum possible sample sizes of 91 and 62 under
binormal and biexponential assumptions, respectively, based on the results from Table 2.
In this test, the boundaries for the normalized AUC statistic, Zj, can be calculated as
(c1 = −b1 = 2.39, c2 = −b2 = 2.29, c3 = −b3 = 2.20). During the comparative diagnostic
trial, Zj is computed at the jth interim analysis and compared with these critical boundaries.
A signiﬁcant Zj gives early evidence that CT is diﬀerent from PET, and the better imaging
method should be adapted in detecting lung cancer. If there is no signiﬁcance and we have
not ﬁnished the trial on all patients, we will continue recruiting more patients until there
is signiﬁcant evidence in the next analysis. After all patients are scanned, if there is still
no signiﬁcant evidence to support the alternative hypothesis, a conclusion will be made
that CT has the same diagnostic ability as PET, and cheaper CT scanning technique can
be recommended for non-small cell lung cancer diagnosis. Since we already noted that the
expected sample sizes under sequential tests would be as low as 81% of that under the ﬁxed
sample test, the early stopping on the average is ensured by group sequential tests.
AUC is an excellent accuracy measure if two ROC curves do not cross each other. However,
when ROC curves cross, they may have similar AUCs but diﬀerent partial AUCs over a range
of speciﬁcities. Suppose a investigator is interested in whether there is a diﬀerence between
partial AUCs of CT and PET over the false positive rate less than 0.6. In this trial, the
WGJJ statistic then becomes the diﬀerence between the nonparametric estimators of partial
AUCs over high speciﬁcities. An initial guess of partial AUCs is 40% for CT and 55% for
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PET, respectively. With power 0.8, type I error .05 and disease prevalence 0.5, a ﬁxed sample
trial would require 48 patients under the binormal assumption and 55 patients under the
exponential assumption according to Tables 2 and 3, respectively.
If a three-group error spending test is decided for the trial, the maximum possible sample
sizes for both arms would be 54 and 62 under binormal and biexponential assumptions,
respectively, based on the results in Tables 2 and 3. The boundaries of three stages for
the normalized partial AUC diﬀerences are also (c1 = −b1 = 2.39, c2 = −b2 = 2.29, c3 =
−b3 = 2.20). Similar as comparative diagnostic trial based on AUC, the normalized test
statistic Zj based on partial AUC is computed based on accruing patients at the jth stage
and corresponding decision will be based on whether Zj crosses the boundaries. Note the
maximum possible sample sizes are smaller for the sequential trials comparing partial AUCs
than those for AUCs. This is due to the fact that partial AUC estimator is less variable than
AUC estimator.
To the best of our knowledge, no actual trials in diagnostic medicine have been conducted
sequentially. To illustrate the details of calculations of monitoring decisions, we simulated a
set of simple hypothetical outcomes from PET and CT scans in aforementioned lung cancer
diagnostic trials. Suppose an investigator has decided to conduct a three-group sequential
trial to compare the accuracy of CT and PET procedures. Under the binormal assumption,
the maximum possible sample size was initially 91 in total based on the 80% power and
0.05 type I error. We simulated binormal data as measurements from 30 subjects at the ﬁrst
look. We then calculated interim contrast Δˆ1 = 0.0259, its standard error σΔ1 = 0.0673, and
the interim normalized statistic Z1 = Δˆ1/σΔ1 = 0.3848. Since Z1 fell within the boundary
(c1 = −b1 = 2.39), we continued with the second look at 30 more simulated measurements. At
the second look, we calculated interim contrast Δˆ2 = 0.1469, its standard error σΔ2 = 0.0534,
and the interim normalized statistic Z2 = Δˆ2/σΔ2 = 2.7510 from all 60 subjects. Now Z2
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was outside the boundary (c2 = −b2 = 2.29), thus we stopped recruiting more subjects and
came to a conclusion that PET has better accuracy to stage lung cancer than CT.
7. Discussion
In this article, we described that after modiﬁcation the sequential WGJJ statistic behaves
like the Brownian motion process, therefore, can be readily implemented using standard
statistical software. The WGJJ statistic includes a large family of nonparametric estimators
in comparative diagnostic tests, oﬀering great modeling ﬂexibility. We also proposed a semi-
parametric method for comparing two diagnostic tests based on multivariate proportional
hazard models. With correct model speciﬁcation, the semiparametric method can allow
survival outcome measurements in the presence of censoring.
Calculating sample size is an important issue when performing group sequential trials.
We illustrated an example of sample size determination based on binormal distribution
assumptions. If a pilot study is available, sample sizes can be empirically determined from
our results. Otherwise, conservative sample size can be determined with the knowledge of
the AUCs and their correlation from Equation (2).
Both nonparametric AUC and partial AUC estimators, as special cases of the WGJJ
statistics, were illustrated in sequential lung cancer trials for comparing the staging accuracy
of non-small cell cancer. Accurate staging diagnosis could guide surgery to help prolong
patients’ life or even cure the patients at early stages of lung cancer, one of top killer diseases.
Therefore, designing comparative trials for the accuracy of scan imaging techniques is rather
important at this point, and our nonparametric estimator provides a robust and eﬃcient way
to sequentially compare techniques in their staging ability. Other examples may be found on
clinincaltrials.gov, which is a website developed by the National Institutes of Health and the
Food and Drug Administration to provide information for federally and privately supported
clinical trials. One ongoing trial is titled as “Comparison of Cardiac Computed Tomographic
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Angiography (CTA) to Tc-99m Single Photon Emission Computed Tomography (SPECT)”
with the purpose of comparing the accuracy of CT and SPECT. In this trial, diagnostic
tests are expensive, and the patients’ disease status are obtained before tests. These are
good logistics for implementing our sequential methods in this trial.
As a ﬁnal note, in diagnostic imaging trials the results are usually immediately available.
The patients’ disease status are obtained before tests or shortly after tests. These provide
good logistics for conducting sequential diagnostic trials. However, sometimes in biomarker
studies it may take a long time to verify true disease status. Also, one may want to look at
Youden index or ﬁnd ”optimal” thresholds in addition to comparing diagnostic tests. It will
be our future topics to develop proper sequential designs for these issues.
Supplementary Materials
Web Appendix is available under the Paper Information link at the Biometrics website
http://www.biometrics.tibs.org.
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Table 1: Type I error with the nominal level α = 0.05 in the group sequential designs
m WGJJ statistic Parametric Semiparametric
(n) Binorm Bilog Biexp Binorm Bilog Biexp Binorm Bilog Biexp
Fixed sample design (J = 1)
50 6.9% 6.6% 5.6% 4.7% 12.0% 0.8% 31.5% 30.4% 5.5%
100 4.5% 6.0% 6.2% 4.1% 21.6% 1.4% 81.2% 80.7% 5.6%
200 5.6% 6.4% 4.0% 4.0% 37.5% 0.8% 88.6% 90.6% 5.5%
Three-group sequential design (J = 3)
OBF 50 4.3% 5.2% 5.2% 5.0% 30.1% 1.0% 77.0% 75.8% 6.6%
100 4.2% 3.3% 3.7% 2.3% 43.8% 0.4% 98.3% 97.4% 6.1%
200 4.7% 5.9% 6.4% 4.5% 62.9% 1.5% 100.0% 100.0% 5.3%
POC 50 5.5% 6.7% 5.7% 4.4% 26.1% 0.8% 69.7% 66.8% 6.8%
100 5.3% 4.5% 5.0% 3.3% 41.4% 0.3% 96.5% 95.5% 6.5%
200 4.7% 6.0% 6.5% 4.1% 60.6% 1.3% 100.0% 100.0% 5.0%
Four-group sequential design (J = 4)
OBF 50 4.7% 3.6% 5.3% 4.2% 33.8% 0.4% 92.5% 92.8% 6.6%
100 4.3% 4.6% 5.2% 3.9% 52.4% 1.0% 100.0% 99.6% 6.5%
200 5.8% 4.8% 5.4% 4.1% 72.6% 0.3% 100.0% 100.0% 4.9%
POC 50 4.5% 6.2% 6.0% 3.4% 30.8% 0.7% 88.7% 87.6% 6.2%
100 5.4% 3.6% 5.8% 4.9% 48.0% 1.2% 99.9% 99.0% 6.1%
200 4.8% 5.1% 5.7% 3.8% 69.4% 0.5% 100.0% 100.0% 5.3%
Five-group sequential design (J = 5)
OBF 50 4.9% 4.5% 5.8% 3.9% 40.8% 0.5% 97.4% 97.4% 5.7%
100 4.4% 5.6% 4.7% 5.1% 60.4% 0.6% 100.0% 99.8% 5.3%
200 4.5% 4.5% 5.7% 3.5% 78.8% 0.4% 100.0% 100.0% 5.0%
POC 50 5.9% 5.2% 6.0% 4.1% 35.5% 0.7% 95.2% 94.7% 5.3%
100 4.4% 5.9% 5.1% 3.1% 55.6% 1.2% 100.0% 99.8% 5.0%
200 5.4% 5.4% 6.0% 3.8% 75.9% 1.4% 100.0% 100.0% 5.0%
The rejection rate with 1000 realizations. The 95% prediction interval is (5.0% ± 1.4%).
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Table 2: Maximum possible number of subjects in both arms for testing ΔA or ΔpA in three-
group analysis (and ﬁxed sample analysis) with 1−β = 0.80 and α = 0.05 under the bivariate
normal distribution
ΔA = ΩA1 − ΩA2
ΩA1 \ΩA2 0.750 0.800 0.850 0.900 0.950 0.975
0.700 929 (832) 217 (195) 91 (81) 49 (44) 32 (29) 28 (25)
0.750 NA 793 (710) 182 (163) 76 (68) 43 (38) 36 (32)
0.800 NA 634 (568) 143 (128) 62 (55) 48 (43)
0.850 NA 456 (408) 103 (92) 68 (61)
0.900 NA 267 (239) 116 (103)
0.950 NA 416 (372)
ΔpA = ΩpA1 − ΩpA2
ΩpA1 \ΩpA2 0.350 0.400 0.450 0.500 0.550 0.575
0.300 732 (655) 174 (156) 72 (65) 38 (34) 24 (21) 20 (18)
0.350 NA 675 (604) 156 (140) 64 (57) 35 (31) 28 (25)
0.400 NA 573 (513) 129 (116) 54 (48) 41 (36)
0.450 NA 436 (390) 97 (87) 62 (56)
0.500 NA 273 (244) 115 (103)
0.550 NA 505 (452)
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Table 3: Maximum possible number of subjects in both arms for testing ΔA or ΔpA in three-
group analysis (and ﬁxed sample analysis) with power 1− β = 0.80 and α = 0.05 under the
bivariate exponential distribution
ΔA = ΩA1 − ΩA2
ΩA1 \ΩA2 0.750 0.800 0.850 0.900 0.950 0.975
0.700 1244 (1113) 293 (262) 122 (109) 65 (58) 39 (35) 32 (28)
0.750 NA 1094 (979) 253 (226) 104 (93) 54 (49) 42 (37)
0.800 NA 914 (818) 206 (184) 83 (74) 58 (52)
0.850 NA 705 (631) 152 (136) 90 (80)
0.900 NA 461 (412) 180 (161)
0.950 NA 975 (872)
ΔpA = ΩpA1 − ΩpA2
ΩpA1 \ΩpA2 0.350 0.400 0.450 0.500 0.550 0.575
0.300 852 (763) 203 (182) 84 (76) 44 (39) 26 (24) 21 (19)
0.350 NA 785 (703) 183 (164) 75 (67) 39 (35) 30 (27)
0.400 NA 680 (609) 154 (138) 62 (55) 43 (39)
0.450 NA 539 (482) 117 (104) 69 (62)
0.500 NA 362 (324) 142 (127)
0.550 NA 781 (699)
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